Orchestra BioMed Holdings, Inc.
OBIO · XNASCIK 1814114fmd_1Q2ZTZPRT84CXHP13Z07PYXPHGManufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Jan 02, 2020 to Sep 30, 2026, 25 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | – | 4 | 3 | 3 | 33 |
| Cost of revenue | – | 0 | 0 | 0 | 0 |
| Net interest income | – | 0 | 4 | – | – |
| Gross profit | – | 3 | 3 | 2 | 33 |
| Realized investment gains (losses) | – | 1 | (0) | (0) | – |
| Research and development | – | 22 | 34 | 43 | 58 |
| Selling, general and administrative | – | 14 | 20 | 24 | 27 |
| Operating income | (0) | (33) | (52) | (64) | (52) |
| Interest expense | – | 1 | 1 | 0 | – |
| Interest and investment income | 0 | 0 | – | – | – |
| Other non-operating income (expense) | – | – | – | (0) | – |
| Income tax expense | – | – | – | – | 0 |
| Net income | (0) | (34) | (49) | (61) | (53) |
| Net income to common shareholders | – | – | – | (61) | (53) |